A new treatment paradigm
for Respiratory Long COVID
The current view is that Respiratory Long COVID is caused by lung scarring. Our research suggests it is driven by a novel mechanism, which can be diagnosed using a proprietary biomarker and targeted with repurposed drugs.
Respiratory Long COVID: 4M+ U.S. adults with no approved treatment options.
Sources: NIAMS, CDC, NHIS 2023, PubMed
~60%
Test positive for our proprietary biomarker
Zero
FDA-approved treatments
With the field focused on scarring, our data points to a reversible disease mechanism.
Lung scarring occurs in patients after severe acute COVID-19, and in mouse models of disease. These observations have led the field to anchor on lung scarring as the mechanism to target in drug trials.
In practice, most patients with Respiratory Long COVID had mild acute COVID-19, and show no evidence of scarring at all.
The primary culprit is a neuroimmune mechanism.
This mechanism can be quantitatively measured using standard clinical testing and targeted with existing drugs, opening a new and reversible treatment target that the field has overlooked.
The primary culprit is a neuroimmune mechanism.
Research led by our Ivy League academic team has shown that this mechanism can be quantitatively measured using standard clinical testing and targeted with existing drugs. Our findings represent a breakthrough in Long COVID research, which has long been limited to subjective symptom scores and poorly validated disease targets.
100+
Patient cohortSupported by real-world clinical evidence in large retrospective cohorts.
The drugs exist. The patients exist.
What's missing is the bridge.
First mover
First mover in a large, untapped U.S. market.
Proprietary biomarker
The first quantitative biomarker for Long COVID, which enables accurate patient selection and measurement of treatment response in clinical trials.
Clinical evidence
Real-world evidence of therapeutic efficacy in a large cohort at an Ivy League academic clinic.
Broad IP
Exclusive rights to a broad patent filing that covers this treatment and 10+ other promising drug classes for Respiratory Long COVID.
Capital efficient
A capital-efficient and well-precedented pathway to commercial success through licensing method-of-use patents to pharmaceutical partners.
Expert team
An established team with world-class expertise in pulmonary medicine, academic research, regulatory strategy, patent law, tech startups, and pharmaceutical dealmaking.
From discovery to commercialization
Discovery
CompleteIdentification of a specific neuroimmune pathway that drives Respiratory Long COVID, distinct from the lung scarring hypothesis that has shaped the field for years.
Validation
CompletePeer-reviewed real-world evidence that supports this pathway as a bona fide therapeutic target.
Protection
CompleteExclusive rights to a patent family covering broad claims across post-viral respiratory indications and 10+ mechanistically targeted drug classes.
Commercialization
ActiveAdvancing toward a strategic partnership to pursue prospective clinical testing and bring our therapies efficiently to market.